

FDA Trends: Path to Approval

TABLE OF CONTENTS

Introduction

Section 1

- 1.1 - Basic Approval Trends Over Three Decades and Four PDUFAs
- 1.2 - Time, Cost, and Success Rates
- 1.3 - Premium for Novelty
- 1.4 - Meeting Effect
- 1.5 - CROs vs. SMEs vs. MNCs

Section 2

- 2.1 - Rap Against Follow-ons
- 2.2 - Basic Approval Trends: NDAs, BLAs & Efficacy Supplements
- 2.3 - Metrics for Supplemental Indications: Time & Therapeutic Area
- 2.4 - Resubmission and Manufacturing Supplements

Section 3

- 3.1 - Basic Approval Trends
- 3.2 - What do these Programs do...Really?
- 3.3 - How to Maximize the Benefits

Section 4

- 4.1 - Basic Product Trends
- 4.2 - Regulatory Science Challenge
- 4.3 - What's Coming Down the Pike?

Section 5

- 5.1 - Basic Trends for ANDA Approvals
- 5.2 - Post-PDUFA V Paradigm: GDUFA, Biosimilars and Drug Shortage
- 5.3 - Impacts of the Global Marketplace

Section 6

- 6.1 - FDA Workload: Is the Agency Gaining or Losing Ground?
- 6.2 - Regulatory Burden for Industry
- 6.3 - Regulatory Outsourcing

Section 7

- 7.1 - Therapeutic Area Impacts: Nature of the Beast!
- 7.2 - FDA Review Division Delays
- 7.3 - Special Case

Section 8

- 8.1 - What PDUFA V tells us about the PDUFA Process
- 8.2 - Latest Studies
- 8.3 - Best Practices

Section 9

- 9.1 - How we got Here and Where are we Heading?
- 9.2 - Prospects for Harmonization
- 9.3 - Proving Value vs. Benefit/Risk
- 9.4 - Social Media to the Rescue

Section 10

- 10.1 - Updates: R&D Trends in 2014
- 10.2 - Updates: R&D Trends in 2015
- 10.3 - What to expect in 2016 and beyond

Summary & Glossary